CompanyGraph
At a glance
- Depends onMidstream position: 5 outgoing, 4 incoming connections
- FinancialsAltman Z-Score 11.65: safe zone
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
3.23BCNY478.55M · vs all stocks (USD)
Revenue (TTM)
373.85MCNY55.44M · vs all stocks (USD)
Profit Margin
-20.49%Beta
-0.6090xvs all stocks
52-Week Change
-27.47%vs all stocks
Market Capitalization
3.23BCNY478.55M · vs all stocks (USD)
Enterprise Value
2.91BCNY431.98M · vs all stocks (USD)
Price to Sales (TTM)
8.71xPrice to Book (MRQ)
2.21xEnterprise to Revenue
7.79xEnterprise to EBITDA
-157.69xGross Margin
24.35%Profit Margin
-20.49%Operating Margin
-9.53%Return on Assets (TTM)
-3.24%Return on Equity (TTM)
-5.07%Revenue (TTM)
373.85MCNY55.44M · vs all stocks (USD)
Revenue per Share (TTM)
2.88CNYUpdated Aug 19, 2026Quarterly Revenue Growth
-4.60%Gross Profit (TTM)
74.19MCNY11.00M · vs all stocks (USD)
EBITDA (TTM)
22.19MCNY3.29M · vs all stocks (USD)
Net Income (TTM)
-76.61MCNY-11.36M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
-3.58%Operating Cash Flow (TTM)
414.13KCNY61.42K · vs all stocks (USD)
Levered Free Cash Flow (TTM)
-9.46MCNY-1.40M · vs all stocks (USD)
Payout Ratio
0.00%Revenue
378.34MCNYFY2025 · Dec 31, 2025Cost of Goods Sold
278.55MCNYFY2025 · Dec 31, 2025Gross Profit
99.80MCNYFY2025 · Dec 31, 2025Operating Income
-47.65MCNY-7.07M · vs all stocks (USD)
Pre-tax Income
-72.39MCNYFY2025 · Dec 31, 2025Income Tax Expense
-2.72MCNYFY2025 · Dec 31, 2025Net Income
-69.66MCNYFY2025 · Dec 31, 2025EBIT
-72.23MCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
22.19MCNYFY2025 · Dec 31, 2025Research & Development
42.68MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
35.08MCNYFY2025 · Dec 31, 2025Other Operating Expenses
10.43MCNYFY2025 · Dec 31, 2025Non-operating Interest Income
896.67KCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
151.03KCNYFY2025 · Dec 31, 2025EPS (Basic)
-0.5500CNYFY2025 · Dec 31, 2025EPS (Diluted)
-0.5500CNYFY2025 · Dec 31, 2025Basic Shares Outstanding
126.66MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
126.66MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-69.66MCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
-102.47MCNYFY2025 · Dec 31, 2025Free Cash Flow
-146.92MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
104.64MCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-69.66MCNYFY2025 · Dec 31, 2025Other Non-cash Items
1.30MCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-15.07MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-19.04MCNYFY2025 · Dec 31, 2025Capital Expenditures
-44.45MCNYFY2025 · Dec 31, 2025Purchase of Investments
-870.00MCNYFY2025 · Dec 31, 2025Sale of Investments
985.00MCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
70.54MCNYFY2025 · Dec 31, 2025Other Financing Charges
-1.21MCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
-1.21MCNYFY2025 · Dec 31, 2025Shares Outstanding
126.54MSharesUpdated Aug 19, 2026Float Shares
56.94MSharesUpdated Aug 19, 2026% Held by Insiders
56.13%vs all stocks
% Held by Institutions
0.60%vs all stocks
Total Cash (MRQ)
231.23MCNY34.29M · vs all stocks (USD)
Total Cash per Share (MRQ)
1.83CNYUpdated Aug 19, 2026Total Debt (MRQ)
3.28MCNY486.85K · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.0022xCurrent Ratio (MRQ)
4.11xBook Value per Share (MRQ)
11.65CNYUpdated Aug 19, 2026Total Assets
1.67BCNY246.96M · vs all stocks (USD)
Total Current Assets
584.95MCNYFY2025 · Dec 31, 2025Total Liabilities
181.12MCNYFY2025 · Dec 31, 2025Total Non-current Assets
1.08BCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
35.15MCNYFY2025 · Dec 31, 2025Total Current Liabilities
145.97MCNYFY2025 · Dec 31, 2025Cash
104.64MCNYFY2025 · Dec 31, 2025Cash Equivalents
35.63MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
140.26MCNYFY2025 · Dec 31, 2025Other Short-term Investments
105.15MCNYFY2025 · Dec 31, 2025Accounts Receivable
58.59MCNYFY2025 · Dec 31, 2025Inventory
181.61MCNYFY2025 · Dec 31, 2025Accounts Payable
118.01MCNYFY2025 · Dec 31, 2025Short-term Debt
1.01MCNYFY2025 · Dec 31, 2025Other Current Liabilities
7.58MCNYFY2025 · Dec 31, 2025Long-term Debt
2.24MCNYFY2025 · Dec 31, 2025Common Stock (Book)
126.54MCNYFY2025 · Dec 31, 2025Retained Earnings
667.77MCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
1.48BCNY220.10M · vs all stocks (USD)
52-Week Low
19.33CNYUpdated Aug 19, 202652-Week High
36.34CNYUpdated Aug 19, 202652-Week Change
-27.47%vs all stocks
Beta
-0.6090xvs all stocks
50-Day MA
22.76CNYUpdated Aug 19, 2026200-Day MA
27.35CNYUpdated Aug 19, 2026Avg 10-Day Volume
4.05MSharesUpdated Aug 19, 2026Avg 30-Day Volume
3.56MSharesUpdated Aug 19, 2026Diluted EPS (TTM)
-0.6000CNYUpdated Aug 19, 2026Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Financial Health
Altman Z-Score 11.65: safe zoneNotable
Altman Z-Score: 11.65
Supply Chain
Midstream position: 5 outgoing, 4 incoming connectionsNotable
Outgoing: 5.00Incoming: 4.00
Companies that share the same coordination system — how they create, deliver, or capture value.
Onconic Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Anhui Sunhere Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Chison Medical Technologies Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Jenscare Scientific Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Guangdong Transtek Medical Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
G2GBio Inc.
Tier 1ProductionApproval-Gated PipelineRule
Orthofix Medical Inc.
Tier 1ProductionApproval-Gated PipelineRuleFlow
ProKidney Corp
Tier 1ProductionApproval-Gated PipelineRule
Jiangsu Hanbon Science & Technology Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Beijing Leadman Biochemistry Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule